- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02905981
Triferic IRIDA (Iron-Refractory Iron-Deficiency Anemia) Protocol
Triferic (Ferric Pyrophosphate Citrate) Administered Orally With Shohl's Solution for the Treatment of Iron-Refractory Iron-Deficiency Anemia
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is an open label, 3-period study assessing the safety, efficacy, and pharmacokinetics of Triferic and Shohl's solution administered orally to patients with IRIDA. A total of 28 patients stratified by 4 age groups (age 0 to <6 years, age 6 to <12 years, age 12 to <18 years, and age >=18 years) will be studied.
Total participation in the study is between 4 weeks (Period 1) and 12 months (Periods 1, 2, and 3), depending upon how many Periods each patient participates in. Following screening, in Period 1 (iron absorption testing) patients undergo oral iron absorption testing during 3 visits to confirm that they adequately absorb iron from Triferic when it is administered with Shohl's solution ('Triferic responders': patients with a maximal increase from baseline in serum iron concentration >100 micrograms per deciliter (μg/dL) following an oral Shohl's solution and Triferic dose).
The 'Triferic responders' from Period 1 are then invited to participate in Period 2 (dose titration). The patients will receive Shohl's solution and Triferic orally up to 3 times per day for 4 months, titrated as needed based on laboratory results and patient tolerance, to determine whether their hemoglobin levels respond to this treatment. Period 2 'hemoglobin responders' (patients with an increase from baseline in hemoglobin (Hgb) concentration ≥1.0 grams per deciliter (g/dL) at Visit 9) will be invited to participate in period 3.
In Period 3 patients will receive Shohl's solution and Triferic orally up to 3 times per day for an additional 6 months to determine whether the hemoglobin response observed in Period 2 is sustainable. During Period 3, Shohl's solution and Triferic dose and frequency may continue to be titrated as needed based on laboratory results and patient tolerance.
A follow-up visit will occur approximately 1 week after the last completed Period study visit, regardless of the Period that the patient completes the study.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Adult patients have provided informed consent and have signed the informed consent form. For pediatric patients, parents/legal guardians of the patient have the ability to understand the requirements of the study and have demonstrated a willingness to have their child comply with all study procedures by signing the informed consent form. Where applicable, assent of the pediatric patient has also been obtained for all study procedures prior to any study-related activities.
- Patient has a history of congenital hypochromic microcytic anemia.
- Patient has a mean corpuscular volume (MCV) ≤75 fluid ounce (fL) at screening.
- Patient has a serum transferrin saturation ≤15% at screening.
- Patient has a history of no or incomplete response to oral iron therapy.
- Patient has a history of no or incomplete response to intravenous iron administration.
- Patient has a history of hepcidin concentration ≥10 nanograms per milliliter (ng/mL) (3.58 nanometer (nM)) off iron supplements, adjusted for the specific hepcidin assay used to be at least 1 standard deviation (SD) greater than the mean for patients with iron-deficiency anemia.
- Patient is documented to have homozygous or compound heterozygous pathogenic mutations in Transmembrane Serine Protease 6 (TMPRSS6) in a Clinical Laboratory Improvement Amendments (CLIA)-certified laboratory.
- Patient has appropriate laboratory values for their disease state at screening (per investigator judgment).
- Patient has no significant abnormal findings on physical examination at screening that would preclude participation in the study (per investigator judgment).
- If the patient is female, she must be pre-pubertal, have had documented surgical sterilization ≥2 years prior to screening, or be practicing adequate birth control. All female patients 9 years of age and older, and also any who have reached menarche before age 9 years, must have a negative serum pregnancy test during screening. It is the investigator's responsibility to determine whether the patient has adequate birth control for study participation.
Exclusion Criteria:
- Patient has had intravenous (IV) or oral iron supplements within 2 weeks prior to Visit 2.
- Patient has had a blood transfusion within 3 months prior to Visit 2.
- Patient is receiving intravenous or oral antibiotics or antifungals for any infectious process. Prophylactic antibiotics administered on a regular basis are allowed. Otherwise-eligible patients may be rescreened when they have recovered from any acute illnesses.
- Patient has a body weight of <11 lbs (5 kg) at screening.
- Patient has participated in an investigational drug study within the 30 days prior to Visit 2.
- Patient has any condition that, in the opinion of the investigator, is likely to prevent the patient from complying with or successfully completing the protocol.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Period 1: Iron Absorption Tests
During 3 consecutive weekly study visits, patients will receive Fer-In- Sol orally 3 milligram iron per kilogram (mg Fe/kg) body weight, Shohl's solution 0.67 millimoles per kilogram (mmol/kg) followed 5 - 15 minutes later by Fer-In- Sol orally 3 mg Fe/kg body weight, and Shohl's solution 0.67 mmol/kg followed 5 - 15 minutes later by Triferic orally 3 mg Fe/kg body weight (respectively).
All oral doses will be administered by study personnel at the research center.
Blood tests will be conducted following each administration in order to measure iron absorption to see if patients qualify for Period 2.
|
Fer-In-Sol is an over-the-counter oral iron supplement.
It will be administered during Period 1 at a dose of 3 mg/kg body weight.
Other Names:
Shohl's solution will be supplied as 500-milliliter (mL) bottles containing citric acid United States Pharmacopeia (USP) 640 milligrams per 5 milliliters (mg/5 mL) and hydrous sodium citrate USP 490 mg/5 mL.
It will be administered during all Periods at a dose of 0.67 mmol/kg body weight.
Other Names:
Triferic is an iron salt that is approved by the Food and Drug Administration (FDA) for the maintenance of hemoglobin in patients with end stage kidney disease on hemodialysis.
It is experimental in this study because it has not yet been approved for patients with IRIDA.
It will be administered during Period 1 at a dose of 3 mg/kg body weight.
In Periods 2 and 3 the dose may be adjusted based on lab results.
Other Names:
|
Experimental: Period 2: Dose Titration
Patients who qualified as 'Triferic responders' in Period 1 will participate in Period 2. Patients will be given oral Shohl's solution and Triferic to administer at home 3 times per day, with the dose being titrated higher or lower based on lab results.
The initial dose will be the same as Period 1 (Shohl's solution 0.67 mmol/kg followed 5 - 15 minutes later by Triferic orally 3 mg Fe/kg body weight) but may be adjusted during Period 2 based on lab results.
Period 2 will involve 5 study visits, scheduled every 4 weeks.
At the end of Period 2, blood tests will be performed to determine if patients qualify for Period 3.
|
Shohl's solution will be supplied as 500-milliliter (mL) bottles containing citric acid United States Pharmacopeia (USP) 640 milligrams per 5 milliliters (mg/5 mL) and hydrous sodium citrate USP 490 mg/5 mL.
It will be administered during all Periods at a dose of 0.67 mmol/kg body weight.
Other Names:
Triferic is an iron salt that is approved by the Food and Drug Administration (FDA) for the maintenance of hemoglobin in patients with end stage kidney disease on hemodialysis.
It is experimental in this study because it has not yet been approved for patients with IRIDA.
It will be administered during Period 1 at a dose of 3 mg/kg body weight.
In Periods 2 and 3 the dose may be adjusted based on lab results.
Other Names:
|
Experimental: Period 3: Hemoglobin Maintenance
Patients who qualified as 'hemoglobin responders' in Period 2 will participate in Period 3. Patients will continue to take Shohl's solution and Triferic at their titrated dose for an additional six months to confirm that their hemoglobin can be maintained over an extended period of time.
The period will be comprised of 3 study visits, scheduled every 8 weeks.
|
Shohl's solution will be supplied as 500-milliliter (mL) bottles containing citric acid United States Pharmacopeia (USP) 640 milligrams per 5 milliliters (mg/5 mL) and hydrous sodium citrate USP 490 mg/5 mL.
It will be administered during all Periods at a dose of 0.67 mmol/kg body weight.
Other Names:
Triferic is an iron salt that is approved by the Food and Drug Administration (FDA) for the maintenance of hemoglobin in patients with end stage kidney disease on hemodialysis.
It is experimental in this study because it has not yet been approved for patients with IRIDA.
It will be administered during Period 1 at a dose of 3 mg/kg body weight.
In Periods 2 and 3 the dose may be adjusted based on lab results.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Efficacy of Triferic Delivered to IRIDA Patients:Change in Hemoglobin (Hgb)
Time Frame: 4 months
|
The efficacy will be done by assessing the change from baseline in hemoglobin concentration
|
4 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Efficacy of Triferic Being Delivered to Iron-refractory Iron Deficiency Anemia (IRIDA) Patients:Change in Serum Iron
Time Frame: 4 months
|
The efficacy will be done by assessing the change from baseline in serum iron
|
4 months
|
The Efficacy of Triferic Being Delivered to IRIDA Patients:Change From Baseline in Transferrin Saturation (TSAT)
Time Frame: 4 months
|
The efficacy will be done by assessing the change from baseline in TSAT
|
4 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Metabolic Diseases
- Hematologic Diseases
- Nutrition Disorders
- Anemia, Hypochromic
- Iron Metabolism Disorders
- Malnutrition
- Anemia, Iron-Deficiency
- Anemia
- Deficiency Diseases
- Molecular Mechanisms of Pharmacological Action
- Anticoagulants
- Chelating Agents
- Sequestering Agents
- Calcium Chelating Agents
- Citric Acid
- Sodium Citrate
Other Study ID Numbers
- RMFPC-15
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Iron-Refractory Iron-Deficiency Anemia
-
Rockwell Medical Technologies, Inc.CompletedIron-refractory, Iron-deficiency Anemia (IRIDA)United States
-
Pennington Biomedical Research CenterRecruitingIron-deficiency | Iron Deficiency Anemia | Iron Deficiency Anemia TreatmentUnited States
-
King's CollegeCompletedIron-deficiency | Iron Deficiency Anemia | Iron Deficiency (Without Anemia)United States
-
Children's Hospital Los AngelesNot yet recruitingAnemia | Iron Deficiency Anemia | Anemia, Iron Deficiency | IDA - Iron Deficiency AnemiaUnited States
-
Children's Hospital Los AngelesWithdrawnAnemia | Iron-deficiency Anemia | Healthy ControlsUnited States
-
Swiss Federal Institute of TechnologyUnited States Agency for International Development (USAID); Quadram Institute... and other collaboratorsCompletedIron-deficiency | Iron Deficiency Anemia | Iron Deficiency (Without Anemia)Peru
-
Arrowhead Regional Medical CenterRecruitingIron Deficiency Anemia of PregnancyUnited States
-
Société des Produits Nestlé (SPN)CompletedIron-deficiency | Anemia | Iron Deficiency AnemiaPhilippines
-
Swiss Federal Institute of TechnologyUniversity of MalawiCompletedIron-deficiency | Iron Deficiency AnemiaMalawi, Switzerland
-
Johann Wolfgang Goethe University HospitalLudwig-Maximilians - University of MunichCompletedNon-invasive Diagnostics of Iron Deficiency in Surgical Patients by Measuring Zinc Protoporphyrin-IXIron-deficiency | Anemia | Iron Deficiency AnemiaGermany
Clinical Trials on Fer-In-Sol
-
Eunice Kennedy Shriver National Institute of Child...University of IowaCompleted
-
University of Colorado, DenverMassachusetts General Hospital; The Emmes Company, LLC; Health Resources and... and other collaboratorsCompletedInsomnia | Autism Spectrum DisorderUnited States, Canada
-
National Institutes of Health (NIH)CompletedIron DeficiencyUnited States
-
Baylor College of MedicineCompletedIron Deficiency Anemia | Heavy Menstrual Bleeding | Abnormal Uterine BleedingUnited States
-
Instituto de Desarrollo e Investigaciones Pediátricas...UnknownIron-deficiency | AnemiaArgentina
-
The Hospital for Sick ChildrenCanadian Institutes of Health Research (CIHR); Unity Health Toronto; Mount Sinai... and other collaboratorsCompletedNon-anemic Iron DeficiencyCanada
-
National Institute of Allergy and Infectious Diseases...Immune Tolerance Network (ITN)CompletedDiabetes Mellitus, Type 1United States
-
Rockwell Medical Technologies, Inc.CompletedIron-refractory, Iron-deficiency Anemia (IRIDA)United States
-
Yale UniversityCompletedFibrosing Alopecia | Frontal Fibrosing Alopecia | Central Centrifugal Cicatricial AlopeciaUnited States
-
Centers for Disease Control and PreventionUniversity of Miami; Nova Southeastern University; DePaul UniversityCompletedHIV InfectionsUnited States